Screener
Gyre Therapeutics, Inc. GYRE Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Additional paid-in capital | 240,644 | 172,819 |
| Statutory reserve | 3,648 | 3,098 |
| Accumulated deficit | (137,962) | (112,603) |
| Accumulated other comprehensive income (loss) | 1,492 | (908) |
| Total Gyre stockholders’ equity | 107,928 | 62,497 |
| Noncontrolling interest | 34,561 | (2,952) |
| Total equity | 142,489 | 59,545 |
| Total liabilities, Series B preferred stock, redeemable convertible preferred stock, and stockholders’ equity | $199,255 | $219,763 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s total liabilities & equity?
- Gyre Therapeutics, Inc. (GYRE) reported total liabilities & equity of $199.26M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
- Gyre Therapeutics, Inc.'s total liabilities & equity increased by 30.5% year-over-year, from $152.65M to $199.26M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Gyre Therapeutics, Inc.'s total liabilities & equity has grown at a 18.3% compound annual growth rate (CAGR), from $94.85M to $219.76M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Gyre Therapeutics, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude